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The c-erbB2 proto-oncogene encodes a 185 kD transmembrane
glycoprotein and is a member of the epidermal growth factor
(EGF) receptor family (Coussens et al, 1985). Amplification
and/or overexpression of c-erbB2 has been reported in 10—40% of
primary breast cancers, and has been associated with a worse prog-
nosis in patients with node-positive (Slamon et al, 1987, 1989;
Gullick et al, 1991) and node-negative disease (Gullick et al, 1991;
Press et al, 1993, 1997; O￿Malley et al, 1996; Charpin et al, 1997;
Andrulis et al, 1998). A recent review proposed that its over-
expression may be more predictive for overall survival than for
disease-free survival (Clinical Practice Guidelines for the Use of
Tumour Markers in Breast Cancer and Colorectal Cancer, 1996),
suggesting that the prognostic effect of c-erbB2 overexpression
may be on the response to anti-cancer treatment following relapse.
c-erbB2 may be a predictor of resistance to hormonal therapy in
breast cancer. Several small studies demonstrated that c-erbB2
overexpression/amplification in patients with breast cancer was
associated with a lower response rate and duration of response to
first-line hormonal therapy at relapse (Wright et al, 1992; Klijn et
al, 1993; Berns et al, 1995). However, other reports showed no
statistically significant relationship between c-erbB2 overexpres-
sion and response to treatment, and concluded that it had no role in
therapeutic decision-making in advanced breast cancer (Archer et
al, 1995; Elledge et al, 1998).
We undertook a large retrospective study to investigate the rela-
tionship between c-erbB2 overexpression in the primary breast
cancer and the response to first-line endocrine therapy for recur-
rent disease. Previous studies have demonstrated a correlation
between c-erbB2 overexpression in the primary tumour and at
metastatic sites (Niehans et al, 1993). The amplification and over-
expression of the c-erbB2 proto-oncogene detected by Southern
and Northern blotting have been shown to correlate with the
c-erbB2 oncoprotein expression evaluated by Western blotting
and immunohistochemistry (Slamon et al, 1987, 1989).
Immunohistochemistry of the primary tumour is therefore an
appropriate method for evaluating c-erbB2 gene dysregulation in
this group of patients.
MATERIALS AND METHODS
A total of 241 patients of the Breast Unit at Guy￿s Hospital who
had received hormonal therapy as first-line treatment for recurrent
breast cancer following primary surgery were identified from
the database. The database contains information on patient and
tumour characteristics, biological features such as histological
grade and steroid receptor status, details of metastatic involve-
ment, treatment and survival. The patients identified for this retro-
spective study had measurable or evaluable disease. Patients could
have received prior adjuvant chemotherapy, but not prior adjuvant
hormonal therapy or any previous treatment for metastatic disease.
Forty-three patients had received adjuvant chemotherapy.
Sixteen had been treated with melphalan, while the others had
received six cycles of cyclophosphamide (600 mg m—2 intra-
venously (i.v.)), methotrexate (40 mg m—2 i.v.) and 5-fluorouracil
(600 mg m—2 i.v.) on days 1 and 8 of each 28-day cycle (CMF).
Histological grading was performed using the criteria of Bloom
and Richardson with modifications as suggested by Elston (1984).
Oestrogen (ER) and progesterone receptor status were determined
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using the dextran-coated charcoal ligand binding assay (King
et al, 1979) with a value of > 10 fmol mg—1 cytosol protein taken as
positive.
Expression of c-erbB2 oncoprotein was assessed in 5-mm
sections of formalin-fixed, paraffin-embedded primary tumour
tissue using a streptavidin—biotin immunohistochemical tech-
nique. The sections were dewaxed and placed in 0.1% hydrogen
peroxide in methanol (0.01 M) phosphate buffered saline (PBS) at
pH 7.2 (5:3) to block endogenous peroxidase activity. After
washing in distilled water followed by PBS, the sections were
incubated with fetal calf serum (FCS)/PBS (1:4) for 10 min (in
order to reduce non-specific staining with primary antibody).
Sections were then coated with 21 N polyclonal antibody at dilu-
tions of 1/400 and 1/1000 in PBS and left at room temperature
overnight. 21N is a rabbit polyclonal antibody raised to the
predicted amino acid sequence from residues 1243—1255 of the
open reading frame of c-erbB2 (Gullick et al, 1987). The
following day, sections were washed in PBS for 10 min and incu-
bated with secondary antiserum (biotinylated porcine anti-rabbit
immunoglobulin (Daktopatts)) at 1/500 dilution in PBS containing
15% FCS and 3% human serum for 30 min and then rewashed
in PBS. Treatment with avidin—biotin peroxidase complex
(Daktopatts ABC complex) followed for 30 min. Peroxidase
activity was demonstrated using diamino—benzidine solution
(Sigma) and the nuclei were counterstained with haematoxylin.
The specificity of the reaction was confirmed by abolition of
staining following pre-incubation of antibody with the immuniz-
ing peptide. Negative controls in which PBS replaced the primary
antiserum were run with each batch. A previously identified
strongly staining tumour was used as a positive control. Inter- and
intra-assay consistency was maintained by using these controls
with each experiment. Any assay in which either control was
unsatisfactory was repeated.
Previous work had demonstrated no prognostic differences
between weak and strongly staining breast cancers (Barnes et al,
1988), thus tumours demonstrating any membrane staining were
regarded as positive. Positive membrane staining was defined as
coloured reaction product delineating the margins of tumour cells
giving a ￿fish-net￿ pattern (for original photograph see Barnes et
al, 1988). All cases were reviewed by two pathologists and any
disagreements were resolved by consultation. The pathologists
were blinded to treatment outcome.
At relapse, systemic treatment for post-menopausal patients was
tamoxifen 20 mg daily. Pre-menopausal patients were treated with
ovarian irradiation, surgical oophorectomy or tamoxifen 20 mg
daily. The predominant site of relapse was loco-regional soft tissue
in 34%, skeletal in 26%, pleural/pulmonary in 21%, visceral in 5%
and at other sites in 14% of patients.
Complete response (CR), partial response (PR) and stable
disease (SD) were defined according to UICC criteria (Hayward et
al, 1977). Overall response to treatment was defined as a patient
having either CR, PR or SD of more than 6 months. The latter
category was included as patients with stable disease have a
similar survival to those showing a partial response (Manni et al,
1989). The time to progression was defined as the time from
initiation of hormonal therapy to progression of disease, discon-
tinuation of treatment or death.
Differences between categorical variables were determined
using the c2 test. The Yates correction was used for 2 ´ 2 tables.
Time to progression was calculated according to the method of
Kaplan and Meier. The resulting curves were compared using the
log rank test. Multivariate analysis was performed using Cox￿s
proportional hazards method.
Table 1 Characteristics of patients with c-erbB2-negative or c-erbB2-
positive primary tumours
c-erb-B2-negative c-erb-B2-positive
(n = 165) (n = 76)
Age
Median 53 54
Minimum 21 25
Maximum 84 76
n % n %
Menstrual status
Pre 64 39 25 33
Peri 36 22 12 16
Post 63 38 36 47
Uncertain 3 1 2 3
Pregnant/lactating 1 1
Tumour size
≤ 2c m 3 2 2 0 1 7 2 4
> 2 cm and ≤5 cm 112 68 47 65
> 5 cm 20 12 8 11
Unknown 1 4
Stage
Operable, node negative 51 31 19 25
Operable, node positive 111 67 56 74
Operable, node unknown 3 2 1 1
Histological type and grade
Ductal grade I 2 1 1 1
Ductal grade II 82 50 32 42
Ductal grade III 51 31 29 38
Lobular 23 14 7 8
Other 7 4 8 11
ER status
≤ 10 fmole/mg 33 20 19 25
> 10 fmole/mg 132 80 57 75
PR status
≤ 10 fmole/mg 56 39 34 52
> 10 fmole/mg 89 61 32 49
Unknown 20 10
Adjuvant treatment
None 122 74 53 70
Chemotherapy 43 26 23 30
Table 2 Overall response rate following first line endocrine treatment
By c-erbB2 status
CR/PR/SD PD
c-erbB2-negative 92/165 (56%) 73/165 (44%)
c-erbB2-positive 29/76 (38%) 47/76 (62%)
c2 = 5.76, df = 1, P = 0.02
By ER status
CR/PR/SD PD
ER-negative 10/52 (19%) 42/52 (81%)
ER-positive 111/189 (58%) 78/189 (42%)
c2 = 23.9, df = 1, P < 0.0001
Overall response rate was defined as complete response (CR), partial
response (PR) or stable disease (SD) of more than 6 months duration. All
other responses were classified as progressive disease (PD). df, ER,
oestrogen receptor.1222 SJ Houston et al
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RESULTS
The primary tumour from 76 women (32%) stained positively for
c-erbB2. The relationships between c-erbB2 status and established
prognostic features are shown in Table 1. There were no statisti-
cally significant differences between the two groups, in particular
there was no statistically significant relationship between c-erbB2
status and tumour grade (P = 0.32). There was a trend towards an
inverse relationship between c-erbB2 overexpression and ER
status (P = 0.08) and between c-erbB2 overexpression and PR
status (P = 0.11).
Of the patients with c-erbB2-negative primary tumours, 139
(84%) received tamoxifen, three (2%) oophrectomy and 23 (14%)
ovarian ablation at relapse. For the patients with c-erbB2-positive
primary tumours, 72 (95%) were treated with tamoxifen and four
(5%) with ovarian ablation at relapse.
The objective response rate (CR + PR) was significantly greater
in patients with ER-positive or PR-positive tumours compared to
those that were negative (ER 42% vs 17%, P = 0.002; PR 43% vs
26%, P = 0.01). The objective response rates in patients with
c-erbB2-positive tumours were not different from those that
were c-erbB2-negative (29% vs 40%, P = 0.1).
When stable disease for greater than 6 months was included in
the overall response category, the response to treatment was signif-
icantly greater in patients with c-erbB2-negative primary tumours
(56 vs 38%, P = 0.02), and in those that were ER-positive (58% vs
19%, P < 0.0001; Table 2).
ER and c-erbB2 status were combined (Table 3). The response to
endocrine treatment for patients with ER-positive—c-erbB2-positive
primary tumours was significantly lower than that for ER-positive—
c-erbB2-negative primary tumours (24% vs 64%, P = 0.05). There
was no difference in response rate when the ER-negative popula-
tion was divided by c-erbB2 status (5% vs 24%, P = 0.29).
The time to progression (TTP) was significantly shorter in
patients with c-erbB2-positive tumours (median TTP 4.1 months),
compared to those that were c-erbB2-negative (median TTP 8.7
months, P < 0.001; Figure 1). The TTP was further analysed by
univariate and multivariate Cox analyses. In both analyses c-
erbB2-positive status was highly significantly associated with a
shorter TTP (Table 4). The type of endocrine treatment had no
effect on TTP in multivariate analysis (P = 0.4).
A further analysis was performed to determine the influence of
c-erbB2 status in patients with ER-positive tumours treated with
tamoxifen. Of the 170 such patients, 54 (32%) were c-erbB2-posi-
tive. The TTP for ER-positive—c-erbB2-positive patients (median
Table 3 Overall response rate by ER and c-erbB2 status
ER-positive ER-negative
c-erb-B2-positive 15/57 (24%) 1/19 (5%)
c-erb-B2-negative 85/132 (64%) 8/33 (24%)
Overall response rate was defined as complete response (CR), partial
response (PR) or stable disease of more than 6 months duration (SD). There
is a significant difference in overall response rate between ER-positive–
c-erbB2-positive and ER-positive–c-erbB2-negative cases (P = 0.05). There
is no difference between the ER-negative cases when divided by c-erbB2
status (P = 0.29). ER, oestrogen receptor.
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Figure 1 Time to progression by c-erbB2 statusc-erbB2 and endocrine therapy in breast cancer 1223
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TTP 5.5 months) was significantly shorter compared to that for
ER-positive—c-erbB2-negative patients (median TTP 11.2 months),
as shown in Figure 2 (P < 0.001). There was no difference in TTP
when the ER-negative population was analysed according to
c-erbB2 status (data not shown).
DISCUSSION
In this study, positive membrane staining for c-erbB2 in the
primary breast cancer predicted a low response rate and a short time
to progression following first-line endocrine therapy for patients
with recurrent disease. Positive c-erbB2 status was significantly
associated with a shorter time to progression after adjusting for
other known predictive factors such as menstrual status, oestrogen
and progesterone receptor status, histological grade and site of
relapse. Multivariate analysis demonstrated that c-erbB2 status was
the most significant predictive factor for a short time to progression
after initiation of endocrine therapy. In patients with ER-positive
primary tumours, c-erbB2 overexpression defined a subgroup less
likely to respond to endocrine therapy.
The c-erbB2 status of the primary tumour did not influence the
objective response rate (CR + PR) to endocrine therapy. However,
when stable disease of greater than 6 months duration was
included, c-erbB2 overexpression was associated with a reduced
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Figure 2 Time to progression by c-erbB2 status. ER-positive patients treated with tamoxifen
Table 4 Cox model analysis of time to progression
Univariate Multivariate
Variable c2 P-value R.R.a 95% C.I.b c2 P-value R.R.a 95% C.I.b
c-erbB2c 11.40 0.007 1.69 1.26–2.26 11.08 0.009 1.69 1.25–2.29
Age 6.48 0.009 1.02 1.00–1.03 0.08 0.78 1.00 0.98–1.02
Menstrual statusd 8.88 0.003 1.50 1.15–1.97 7.89 0.005 1.48 1.12–1.95
Tumour size 0.46 0.50 1.03 0.95–1.12 0.05 0.83 1.01 0.93–1.10
Stagee 0.44 0.51 1.10 0.83–1.47 0.39 0.53 1.11 0.80–1.53
Histologyf 12.45 0.0004 1.65 1.25–2.16 9.42 0.002 1.54 1.17–2.03
ER statusg 11.60 0.0007 1.82 1.32–2.52 7.85 0.005 1.64 1.18–2.29
Adjuvant treatmenth 3.40 0.07 1.33 0.99–1.79 1.34 0.25 1.20 0.88–1.63
aRelative risk; b95% confidence intervals; cNegative v positive status; dPre- vs post-menopausal; eStage I v stage II disease; fGrade I v Grade II v Grade III;
gNegative v positive status; hNone v anyoverall response rate to treatment. Stable disease was included in
the overall response assessment, as one-quarter of patients had
predominantly skeletal disease. The response assessment is
difficult in this group; the overexpression of c-erbB2 was still
associated with a lower overall response rate after exclusion of
patients with skeletal metastases (data not shown). Also, survival
in patients with stable disease of greater than 6 months duration is
similar to that of patients that achieve a PR to treatment (Manni
et al, 1989). Others groups studying similar patients defined
￿response￿ as CR + PR + SD of more than 6 months duration
(Wright et al, 1992; Klijn et al, 1993; Archer et al, 1995; Berns
et al, 1995; Elledge et al, 1998), and most demonstrated that over-
expression of c-erbB2 reduced the response rate to endocrine
therapy in advanced breast cancer.
As with all retrospective studies, there may have been unex-
pected bias. All patients had relapsed following primary surgery,
had evaluable or assessable disease and received endocrine therapy.
As ER expression in the primary tumour is a strong predictor of
response to endocrine therapy in breast cancer (Rubens and
Hayward, 1980), it is not surprising that most patients in this study
had ER-positive primary tumours. ER expression has been reported
to negatively correlate with c-erbB2 overexpression in an unse-
lected population of patients with breast cancer (Ciocca et al,
1992). In the current study there was a trend towards ER and PR
positivity with c-erbB2 negativity. Although the analysis was based
on the tumour characteristics at presentation rather than at relapse,
evidence suggests that c-erbB2 overexpression is similar in primary
and metastatic disease (Niehans et al, 1993). Although ER loss has
been reported, in most patients with ER-positive primary tumours
the recurrent disease is also ER-positive (Kuukasjarvi et al, 1996).
Other workers have used immunohistochemistry to assess c-
erbB2 status and have demonstrated resistance to endocrine
therapy for patients with recurrent disease (Wright et al, 1992). In
addition, several studies (Borg et al, 1994; Tetu and Brisson, 1994;
Sjogren et al, 1998), and two randomized trials (Carlomagno et al,
1996; Stal et al, 1997), have demonstrated that c-erbB2 over-
expression in the primary breast cancer reduced the benefit from
adjuvant tamoxifen.
Two studies reported that c-erbB2 overexpression did not alter
response to hormonal therapy (Archer et al, 1995; Elledge et al,
1998). The former was based on fewer than 100 patients and so
lacked statistical power. The study of Elledge et al used 205 ER-
positive patients from the Southwest Oncology Group (SWOG)
study 8228 (Ravdin et al, 1992). Their study population differs
from ours in several respects. Their criterion for ER positivity was
set at the lower level of > 3 fmol mg—1 cytosol; in practice, at our
and other institutions, the clinical cut-off value for ER-positivity in
the ligand binding assay was usually > 10 fmol mg—1 (Barnes et al,
1998). All patients in the study of Elledge et al received tamoxifen
as initial therapy for metastatic disease. However, 47% of patients
had metastatic disease at presentation (Elledge et al, 1998)
whereas all patients in our study had relapsed following surgery. In
the SWOG study c-erbB2 status was defined by a scoring system
for membrane staining of tumour cells. Any tumour with more
than 1 in 100 tumour cells stained was deemed c-erbB2-positive.
In the study that we report, any membrane staining was regarded
as positive for c-erbB2.
In their initial analysis c-erbB2 overexpression did not influence
either response rate or time to progression (Elledge et al, 1998).
However, because of issues of reproducibility in the immunohisto-
chemistry, a second independent observer scored the slides. Using
the same scoring systems, in the repeat analysis c-erbB2 over-
expression significantly reduced the time to progression (median
TTP 4 months vs 8 months, P = 0.01). This highlights the
problems of scoring systems and inter-observer variation in immuno-
histochemical assessment of pathological specimens, and under-
mines their conclusion that c-erbB2 overexpression is not associated
with a poorer response to tamoxifen (Elledge et al, 1998). In the
study we report, any membrane staining was regarded as positive and
all slides were examined by two pathologists (who were blinded to
the response data); in patients with ER-positive tumours treated
with tamoxifen, c-erbB2 overexpression significantly reduced
TTP (5.5 months vs 11.2 months, P < 0.001).
Other investigators have used serum erbB2 estimates in breast
cancer patients. The extracellular domain of the c-erbB2 protein
has been found in the sera of 20—40% of patients with metastatic
breast cancer (Leitzel et al, 1992; Kath et al, 1993). In separate
studies using different assays for serum erbB2, elevated pre-
treatment levels predicted a poor response to first-line (Yamauchi
et al, 1997) and second-line endocrine therapy in patients with
metastatic breast cancer (Leitzel et al, 1995). These studies did not
determine the relationship between serum levels of erbB2 and
tissue expression.
Experimental evidence suggests that c-erbB2 overexpression
may modulate response to endocrine therapy. Studies in vitro and in
animal models using the MCF-7 human breast cancer cell line
have demonstrated that transfection with c-erbB2 reduced their
sensitivity to tamoxifen (Benz et al, 1992; Pietras et al, 1995). In
experimental studies, overexpression and/or stimulation of c-erbB2
down-regulated ER expression and activity (Pietras et al, 1995;
Saceda et al, 1996), but other mechanisms have been proposed.
The function of c-erbB2 may not be to bind any ligand directly,
but rather to increase the binding affinity of ligands to
heterodimers of the erb family (Karunagaran et al, 1996). c-erbB2
can form heterodimers with the EGF receptor (erbB1) and neu
differentiation factor (NDF) receptors (erbB3 and erbB4). The
overexpression of c-erbB2 in cell lines reduced the ligand dissoci-
ation rate for both EGF and NDF, whereas the removal of c-erbB2
accelerated the dissociation rate. The prolonged binding of EGF or
NDF resulted in increased activation of the measured cytoplasmic
kinases. This suggests that c-erbB2 may affect the response to a
wide variety of ligands by altering the binding affinities of growth
factor receptors, and its overexpression may result in a growth
advantage for affected cells.
The oestrogenic stimulation of breast cancer cells involves
growth factors for the erb family of receptors (Kern et al, 1990). It
has been demonstrated that patients who had either EGF receptor-
positive and/or c-erbB2-positive disease had a significantly lower
response rate to endocrine therapy than those who were negative
for both (Newby et al, 1997). The overexpression of c-erbB2 may
result in some oestrogenic growth factor pathways becoming
independent of the ER, and explain our observations of relative
resistance to endocrine therapy in such cases.
If c-erbB2 overexpression is a marker of resistance to endocrine
therapy in breast cancer, it may be that these women would be
better treated with chemotherapy. There are conflicting data on
whether overexpression of c-erbB2 predicts for resistance to
different combinations of chemotherapy. Several studies have
suggested that c-erbB2 overexpression may be a marker for
resistance to treatment with adjuvant CMF (Allred et al, 1992;
Gusterson et al, 1992). However, both of these studies included an
endocrine component in the adjuvant therapy. In the study of
1224 SJ Houston et al
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to chemotherapy, and in the study of Allred et al, prednisolone was
added to chemotherapy. The lack of efficacy of adjuvant treatment
in the c-erbB2-positive groups may have been due to differences in
the response to the endocrine component of the adjuvant therapy.
Others have reported that c-erbB2 overexpression predicted for a
better response to CMF chemotherapy in the treatment of
metastatic breast cancer (Klijn et al, 1993; Berns et al, 1995).
The current study has shown that c-erbB2 overexpression,
determined by immunohistochemistry in the primary tumour,
predicted for relative resistance to endocrine therapy in patients
with recurrent breast cancer. Other studies have demonstrated that
overexpression of c-erbB2 negates the benefits of adjuvant tamox-
ifen in patients with ER-positive primary tumours (Carlomagno et
al, 1996; Stal et al, 1997). These observations may influence the
choice of systemic therapy for breast cancer in patients whose
primary tumour overexpressed c-erbB2. A logical extension would
be to inhibit both the ER and c-erbB2 pathways. Experimental
studies using the BT474 human breast cancer line (which
expresses ER and overexpresses c-erbB2) demonstrated that the
combination of tamoxifen and 4D5 (a monoclonal antibody to
c-erbB2) inhibited cell growth significantly more than either
agent alone (Witters et al, 1997). The administration of antibody
to c-erbB2 has proven effective in clinical trials of patients
with primary breast cancers that overexpress c-erbB2 (Baselga
et al, 1996). The combination of endocrine therapy and antibody
to c-erbB2 may be worthy of investigation in patients with
ER-positive tumours that also overexpress c-erbB2.
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